These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24900864)

  • 21. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity.
    Rudolph J; Esler WP; O'connor S; Coish PD; Wickens PL; Brands M; Bierer DE; Bloomquist BT; Bondar G; Chen L; Chuang CY; Claus TH; Fathi Z; Fu W; Khire UR; Kristie JA; Liu XG; Lowe DB; McClure AC; Michels M; Ortiz AA; Ramsden PD; Schoenleber RW; Shelekhin TE; Vakalopoulos A; Tang W; Wang L; Yi L; Gardell SJ; Livingston JN; Sweet LJ; Bullock WH
    J Med Chem; 2007 Oct; 50(21):5202-16. PubMed ID: 17887659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
    Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
    J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of potent, selective, and orally bioavailable 3H-spiro[isobenzofuran-1,4'-piperidine] based melanocortin subtype-4 receptor agonists.
    Guo L; Ye Z; Liu J; He S; Bakshi RK; Sebhat IK; Dobbelaar PH; Hong Q; Jian T; Dellureficio JP; Tsou NN; Ball RG; Weinberg DH; MacNeil T; Tang R; Tamvakopoulos C; Peng Q; Chen HY; Chen AS; Martin WJ; MacIntyre DE; Strack AM; Fong TM; Wyvratt MJ; Nargund RP
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4895-900. PubMed ID: 20621473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design, evaluation, and comparison of ghrelin receptor agonists and inverse agonists as suitable radiotracers for PET imaging.
    Chollet C; Bergmann R; Pietzsch J; Beck-Sickinger AG
    Bioconjug Chem; 2012 Apr; 23(4):771-84. PubMed ID: 22372770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological Modulation of Ghrelin to Induce Weight Loss: Successes and Challenges.
    Schalla MA; Stengel A
    Curr Diab Rep; 2019 Sep; 19(10):102. PubMed ID: 31506846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of DS-1558: A Potent and Orally Bioavailable GPR40 Agonist.
    Takano R; Yoshida M; Inoue M; Honda T; Nakashima R; Matsumoto K; Yano T; Ogata T; Watanabe N; Hirouchi M; Yoneyama T; Ito S; Toda N
    ACS Med Chem Lett; 2015 Mar; 6(3):266-70. PubMed ID: 25815144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Drug with Lipophilicity-Dependent Potency Can Be Metabolically Stable: Discovery of a Potent and Selective Retinoic Acid Receptor-Related Orphan Receptor C2 (RORC2) Inverse Agonist as an Orally Bioavailable Anti-Inflammatory Agent.
    Wang Y; Liu H
    J Med Chem; 2018 Dec; 61(23):10412-10414. PubMed ID: 30507131
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Lesage A; Gibson C; Marceau F; Ambrosi HD; Saupe J; Katzer W; Loenders B; Charest-Morin X; Knolle J
    Front Pharmacol; 2020; 11():916. PubMed ID: 32636746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ghrelin receptor inverse agonists as a novel therapeutic approach against obesity-related metabolic disease.
    Abegg K; Bernasconi L; Hutter M; Whiting L; Pietra C; Giuliano C; Lutz TA; Riediger T
    Diabetes Obes Metab; 2017 Dec; 19(12):1740-1750. PubMed ID: 28544245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
    Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.
    Johnson DS; Stiff C; Lazerwith SE; Kesten SR; Fay LK; Morris M; Beidler D; Liimatta MB; Smith SE; Dudley DT; Sadagopan N; Bhattachar SN; Kesten SJ; Nomanbhoy TK; Cravatt BF; Ahn K
    ACS Med Chem Lett; 2011 Feb; 2(2):91-96. PubMed ID: 21666860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and Optimization of Pyrrolidine Derivatives as Highly Potent Ghrelin Receptor Full Agonists.
    Cooper M; Llinas A; Hansen P; Caffrey M; Ray A; Sjödin S; Shamovsky I; Wada H; Jellesmark Jensen T; Sivars U; Hultin L; Andersson U; Lundqvist S; Gedda K; Jinton L; Krutrök N; Lewis R; Jansson P; Gardelli C
    J Med Chem; 2020 Sep; 63(17):9705-9730. PubMed ID: 32787075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term treatment with the ghrelin receptor antagonist [d-Lys3]-GHRP-6 does not improve glucose homeostasis in nonobese diabetic MKR mice.
    Mosa R; Huang L; Li H; Grist M; LeRoith D; Chen C
    Am J Physiol Regul Integr Comp Physiol; 2018 Jan; 314(1):R71-R83. PubMed ID: 28903914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.
    von Berg S; Xue Y; Collins M; Llinas A; Olsson RI; Halvarsson T; Lindskog M; Malmberg J; Jirholt J; Krutrök N; Ramnegård M; Brännström M; Lundqvist A; Lepistö M; Aagaard A; McPheat J; Hansson EL; Chen R; Xiong Y; Hansson TG; Narjes F
    ACS Med Chem Lett; 2019 Jun; 10(6):972-977. PubMed ID: 31223457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of the potency and pharmacokinetic properties of a macrocyclic ghrelin receptor agonist (Part I): Development of ulimorelin (TZP-101) from hit to clinic.
    Hoveyda HR; Marsault E; Gagnon R; Mathieu AP; Vézina M; Landry A; Wang Z; Benakli K; Beaubien S; Saint-Louis C; Brassard M; Pinault JF; Ouellet L; Bhat S; Ramaseshan M; Peng X; Foucher L; Beauchemin S; Bhérer P; Veber DF; Peterson ML; Fraser GL
    J Med Chem; 2011 Dec; 54(24):8305-20. PubMed ID: 22106937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.
    Xue CB; Chen L; Cao G; Zhang K; Wang A; Meloni D; Glenn J; Anand R; Xia M; Kong L; Huang T; Feng H; Zheng C; Li M; Galya L; Zhou J; Shin N; Baribaud F; Solomon K; Scherle P; Zhao B; Diamond S; Emm T; Keller D; Contel N; Yeleswaram S; Vaddi K; Hollis G; Newton R; Friedman S; Metcalf B
    ACS Med Chem Lett; 2010 Dec; 1(9):483-7. PubMed ID: 24900235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of 3-Cyano- N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1 H-pyrrolo[2,3- b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist.
    Schnute ME; Wennerstål M; Alley J; Bengtsson M; Blinn JR; Bolten CW; Braden T; Bonn T; Carlsson B; Caspers N; Chen M; Choi C; Collis LP; Crouse K; Färnegårdh M; Fennell KF; Fish S; Flick AC; Goos-Nilsson A; Gullberg H; Harris PK; Heasley SE; Hegen M; Hromockyj AE; Hu X; Husman B; Janosik T; Jones P; Kaila N; Kallin E; Kauppi B; Kiefer JR; Knafels J; Koehler K; Kruger L; Kurumbail RG; Kyne RE; Li W; Löfstedt J; Long SA; Menard CA; Mente S; Messing D; Meyers MJ; Napierata L; Nöteberg D; Nuhant P; Pelc MJ; Prinsen MJ; Rhönnstad P; Backström-Rydin E; Sandberg J; Sandström M; Shah F; Sjöberg M; Sundell A; Taylor AP; Thorarensen A; Trujillo JI; Trzupek JD; Unwalla R; Vajdos FF; Weinberg RA; Wood DC; Xing L; Zamaratski E; Zapf CW; Zhao Y; Wilhelmsson A; Berstein G
    J Med Chem; 2018 Dec; 61(23):10415-10439. PubMed ID: 30130103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
    Takahashi B; Funami H; Iwaki T; Maruoka H; Shibata M; Koyama M; Nagahira A; Kamiide Y; Kanki S; Igawa Y; Muto T
    Bioorg Med Chem; 2015 Aug; 23(15):4792-4803. PubMed ID: 26100441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss.
    Esler WP; Rudolph J; Claus TH; Tang W; Barucci N; Brown SE; Bullock W; Daly M; Decarr L; Li Y; Milardo L; Molstad D; Zhu J; Gardell SJ; Livingston JN; Sweet LJ
    Endocrinology; 2007 Nov; 148(11):5175-85. PubMed ID: 17656463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.